Cohen Cheryl

SEC Form 4 insider trading activity

Cohen Cheryl has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Jul 7, 2026.

On the most recent filing, Cohen Cheryl is listed as Director at ImmunityBio, Inc. Inside the rolling window, Cohen Cheryl reported no open-market purchases and 1 open-market sale totaling $1.2M in IBRX.

Companies traded

Other insiders at IBRX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$1.2M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
IBRXSale$1.2MJul 7SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Cohen Cheryl made?

Cohen Cheryl has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.

Which companies does Cohen Cheryl trade?

Cohen Cheryl has filed SEC Form 4 disclosures for 1 company, including IBRX.

When was Cohen Cheryl's most recent SEC Form 4 filing?

Cohen Cheryl's most recent SEC Form 4 filing on Tracefour is dated Jul 7, 2026.

What is Cohen Cheryl's total buy and sell value in the current window?

Inside the rolling retention window, Cohen Cheryl bought $0 and sold $1.2M based on SEC Form 4 filings.

What was Cohen Cheryl's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 131,210 IBRX shares on 2026-07-02, worth $1.2M, per SEC Form 4 filings.